Combining doxorubicin with a phenolic extract from flaxseed oil: Evaluation of the effect on two breast cancer cell lines

Guerriero,Eliana; Sorice,Angela; Capone,Francesca; Storti,Gabriella; Colonna,Giovanni; Ciliberto,Gennaro; Costantini,Susan

doi:10.3892/ijo.2017.3835

Combining doxorubicin with a phenolic extract from flaxseed oil: Evaluation of the effect on two breast cancer cell lines

Authors:
- Eliana Guerriero
- Angela Sorice
- Francesca Capone
- Gabriella Storti
- Giovanni Colonna
- Gennaro Ciliberto
- Susan Costantini
View Affiliations

Affiliations: CROM, Istituto Nazionale Tumori ʻFondazione G. Pascaleʼ ‑ IRCCS, Naples, Italy, Onco-Hematology Department, Avellino Hospital, Avellino, Italy, Medical Informatics Service, University Hospital, Second University of Naples, Naples, Italy, Scientific Direction, Istituto Nazionale Tumori ʻFondazione G. Pascaleʼ ‑ IRCCS, Naples, Italy
Published online on: January 2, 2017 https://doi.org/10.3892/ijo.2017.3835
Pages: 468-476

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most frequently diagnosed forms of cancer and different treatments are used to block its progression. However, it still represents a very common cause of death in women. Doxorubicin (Dox) is reported as an effective agent in breast cancer treatment nonetheless it induces many side‑effects. For this reason, many laboratories are engaged in understanding how it is possible to decrease the drug concentration, considering that one of the possible solutions is to use drug synergy, combining it with natural substances. Recently we showed that a phenolic extract from flaxseed (FS) oil, named PEFSO, induced on MCF‑7 cell line an increase of apoptosis with related modification of G0/G1 phase cell cycle, and the activation of signaling and pro‑oxidant pathways. In this study we present data on the combined effect of Dox and PEFSO on two different breast cancer cell lines to define the conditions to use lower doses of this chemotherapeutic agent. We report the data relating to the ability of this mixture to induce cytotoxicity and apoptosis, cell cycle modification, mitochondrial membrane depolarization and activation of extrinsic and/or intrinsic apoptotic pathway.

View Figures

View References

1	Guerriero E, Sorice A, Capone F, Napolitano V, Colonna G, Storti G, Castello G and Costantini S: Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines. PLos One. 9:e1152872014. View Article : Google Scholar : PubMed/NCBI
2	Iwamoto T: Clinical application of drug delivery systems in cancer chemotherapy: Review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 36:715–718. 2013. View Article : Google Scholar : PubMed/NCBI
3	Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ and Cawkwell L: The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 5:2115–2120. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rashid S, Ali N, Nafees S, Ahmad ST, Arjumand W, Hasan SK and Sultana S: Alleviation of doxorubicin-induced nephrotoxicity and hepatotoxicity by chrysin in Wistar rats. Toxicol Mech Methods. 23:337–345. 2013. View Article : Google Scholar
5	Rai G, Mishra S, Suman S and Shukla Y: Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight. Phytomedicine. 23:233–242. 2016. View Article : Google Scholar : PubMed/NCBI
6	Thakur JS, Chauhan CG, Diwana VK, Chauhan DC and Thakur A: Extravasational side effects of cytotoxic drugs: A preventable catastrophe. Indian J Plast Surg. 41:145–150. 2008. View Article : Google Scholar : PubMed/NCBI
7	Desai AG, Qazi GN, Ganju RK, El-Tamer M, Singh J, Saxena AK, Bedi YS, Taneja SC and Bhat HK: Medicinal plants and cancer chemoprevention. Curr Drug Metab. 9:581–591. 2008. View Article : Google Scholar : PubMed/NCBI
8	Vinod BS, Maliekal TT and Anto RJ: Phytochemicals as chemosensitizers: From molecular mechanism to clinical significance. Antioxid Redox Signal. 18:1307–1348. 2013. View Article : Google Scholar
9	Divakaran SA and Nai CKK: Amelioration of doxorubicin induced cardiotoxicity in tumor bearing mice by ferulic acid: A mechanistic study at cellular and biochemical level. Int J Tumor Ther. 1:6–13. 2012. View Article : Google Scholar
10	Chegaev K, Riganti C, Rolando B, Lazzarato L, Gazzano E, Guglielmo S, Ghigo D, Fruttero R and Gasco A: Doxorubicin-antioxidant co-drugs. Bioorg Med Chem Lett. 23:5307–5310. 2013. View Article : Google Scholar : PubMed/NCBI
11	Goyal A, Sharma V, Upadhyay N, Gill S and Sihag M: Flax and flaxseed oil: An ancient medicine & modern functional food. J Food Sci Technol. 51:1633–1653. 2014. View Article : Google Scholar : PubMed/NCBI
12	Truan JS, Chen JM and Thompson LU: Comparative effects of sesame seed lignan and flaxseed lignan in reducing the growth of human breast tumors (MCF-7) at high levels of circulating estrogen in athymic mice. Nutr Cancer. 64:65–71. 2012. View Article : Google Scholar
13	Sorice A, Guerriero E, Volpe MG, Capone F, La Cara F, Ciliberto G, Colonna G and Costantini S: Differential response of two human breast cancer cell lines to the phenolic extract from flaxseed oil. Molecules. 21:3192016. View Article : Google Scholar : PubMed/NCBI
14	Capone F, Guerriero E, Sorice A, Colonna G, Storti G, Pagliuca J, Castello G and Costantini S: Synergistic antitumor effect of doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines. Sci World J. 2014:4503902014. View Article : Google Scholar
15	Tirosh O, Sen CK, Roy S, Kobayashi MS and Packer L: Neuroprotective effects of alpha-lipoic acid and its positively charged amide analogue. Free Radic Biol Med. 26:1418–1426. 1999. View Article : Google Scholar : PubMed/NCBI
16	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
17	Porichi O, Nikolaidou ME, Apostolaki A, Tserkezoglou A, Arnogiannaki N, Kassanos D, Margaritis L and Panotopoulou E: BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 29:3977–3982. 2009.PubMed/NCBI
18	Stefanowicz-Hajduk J, Bartoszewski R, Bartoszewska S, Kochan K, Adamska A, Kosiński I and Ochocka JR: Pennogenyl saponins from Paris quadrifolia L. induce extrinsic and intrinsic pathway of apoptosis in human cervical cancer HeLa cells. PLoS One. 10:e01359932015. View Article : Google Scholar : PubMed/NCBI
19	Wang G, Zhang J, Liu L, Sharma S and Dong Q: Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PloS One. 7:e517642012. View Article : Google Scholar : PubMed/NCBI
20	Maggio M, Artoni A, Lauretani F, Borghi L, Nouvenne A, Valenti G and Ceda GP: The impact of omega-3 fatty acids on osteoporosis. Curr Pharm Des. 15:4157–4164. 2009. View Article : Google Scholar
21	Rodriguez-Leyva D, Dupasquier CM, McCullough R and Pierce GN: The cardiovascular effects of flaxseed and its omega-3 fatty acid, α-linolenic acid. Can J Cardiol. 26:489–496. 2010. View Article : Google Scholar : PubMed/NCBI
22	Mason JK, Fu M, Chen J and Thompson LU: Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). J Nutr Biochem. 26:16–23. 2015. View Article : Google Scholar
23	Sharifi S, Barar J, Hejazi MS and Samadi N: Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells. Adv Pharm Bull. 5:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
24	Meiyanto E, Fitriasari A, Hermawan A, Junedi S and Susidarti RA: The improvement of doxorubicin activity on breast cancer cell lines by tangeretin through cell cycle modulation. Orient Pharm Exp Med. 11:183–190. 2011. View Article : Google Scholar
25	Cheng YY, Yang JS, Tsai SC, Liaw CC, Chung JG, Huang LJ, Lee KH, Lu CC, Chien HC, Tsuzuki M, et al: The newly synthesized 2-(3-hydroxy-5-methoxyphenyl)-6,7-methylene-dioxyquinolin-4-one triggers cell apoptosis through induction of oxidative stress and upregulation of the p38 MAPK signaling pathway in HL-60 human leukemia cells. Oncol Rep. 28:1482–1490. 2012.PubMed/NCBI
26	Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
27	Yang F, Chen H, Liu Y, Yin K, Wang Y, Li X, Wang G, Wang S, Tan X, Xu C, et al: Doxorubicin caused apoptosis of mesenchymal stem cells via p38, JNK and p53 pathway. Cell Physiol Biochem. 32:1072–1082. 2013. View Article : Google Scholar : PubMed/NCBI
28	Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, Guo N, Muruganujan A, Doremieux O, Campbell MJ, et al: The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 33:D284–D288. 2005. View Article : Google Scholar :
29	Ortiz MA, Lopez-Hernandez FJ, Bayon Y, Pfahl M and Piedrafita FJ: Retinoid-related molecules induce cytochrome c release and apoptosis through activation of c-Jun NH(2)-terminal kinase/p38 mitogen-activated protein kinases. Cancer Res. 61:8504–8512. 2001.PubMed/NCBI
30	Chuang SM, Wang IC and Yang JL: Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis. 21:1423–1432. 2000. View Article : Google Scholar : PubMed/NCBI
31	Ding H, Gabali AM, Jenson SD, Lim MS and Elenitoba-Johnson KS: P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas. J Hematop. 2:195–204. 2009. View Article : Google Scholar : PubMed/NCBI
32	Parrish AB, Freel CD and Kornbluth S: Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol. 5:a0086722013. View Article : Google Scholar : PubMed/NCBI
33	Jin Z and El-Deiry WS: Overview of cell death signaling pathways. Cancer Biol Ther. 4:139–163. 2005. View Article : Google Scholar : PubMed/NCBI
34	Merhi F, Tang R, Piedfer M, Mathieu J, Bombarda I, Zaher M, Kolb JP, Billard C and Bauvois B: Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PloS One. 6:e259632011. View Article : Google Scholar : PubMed/NCBI